Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection.

Détails

Ressource 1Télécharger: 37230973_BIB_73C166DF5907.pdf (2586.36 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_73C166DF5907
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection.
Périodique
Nature communications
Auteur⸱e⸱s
Perez-Saez J., Zaballa M.E., Lamour J., Yerly S., Dubos R., Courvoisier D.S., Villers J., Balavoine J.F., Pittet D., Kherad O., Vuilleumier N., Kaiser L., Guessous I., Stringhini S., Azman A.S.
Collaborateur⸱rice⸱s
Specchio-COVID19 study group
Contributeur⸱rice⸱s
Arm-Vernez I., Bachmann D., Bal A., Barbe R.P., Baysson H., Berthelot J., Bryand-Rumley G., Chappuis F., Collombet P., Coudurier-Boeuf S., de Mestral C., D'ippolito P., Dumont R., El Merjani N., Flahault A., Francioli N., Graindorge C., Harnal S., Hurst S., Lescuyer P., L'Huillier A.G., Loizeau A.J., Lorthe E., Martinez C., Metral-Boffod L., Nehme M., Noël N., Pennacchio F., Posfay-Barbe K.M., Poulain G., Pugin C., Pullen N., Richard V., Rochat D., Samir K., Ramirez H.S., Satin E., Schaller P., Schrempft S., Semaani C., Testini S., Urrutia-Rivas D., Verolet C., Vetter P., Violot G., Wisniak A.
ISSN
2041-1723 (Electronic)
ISSN-L
2041-1723
Statut éditorial
Publié
Date de publication
26/05/2023
Peer-reviewed
Oui
Editeur⸱rice scientifique
Arm-Vernez I Bachmann D. Bal A. Barbe R. P. Baysson H. Berthelot J. Bryand-Rumley G. Chappuis F. Collombet P. Coudurier-Boeuf S. de Mestral C. D'ippolito P. Dumont R. El Merjani N. Flahault A. Francioli N. Graindorge C. Harnal S. Hurst S. Lescuyer P. L'Huillier A. G. Loizeau A. J. Lorthe E. Martinez C. Metral-Boffod L. Nehme M. Noel N. Pennacchio F. Posfay-Barbe K. M. Poulain G. Pugin C. Pullen N. Richard V. Rochat D. Samir K. Ramirez H. S. Satin E. Schaller P. Schrempft S. Semaani C. Testini S. Urrutia-Rivas D. Verolet C. Vetter P. Violot G. Wisniak A.
Volume
14
Numéro
1
Pages
3032
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Résumé
Binding antibody levels against SARS-CoV-2 have shown to be correlates of protection against infection with pre-Omicron lineages. This has been challenged by the emergence of immune-evasive variants, notably the Omicron sublineages, in an evolving immune landscape with high levels of cumulative incidence and vaccination coverage. This in turn limits the use of widely available commercial high-throughput methods to quantify binding antibodies as a tool to monitor protection at the population-level. Here we show that anti-Spike RBD antibody levels, as quantified by the immunoassay used in this study, are an indirect correlate of protection against Omicron BA.1/BA.2 for individuals previously infected by SARS-CoV-2. Leveraging repeated serological measurements between April 2020 and December 2021 on 1083 participants of a population-based cohort in Geneva, Switzerland, and using antibody kinetic modeling, we found up to a three-fold reduction in the hazard of having a documented positive SARS-CoV-2 infection during the Omicron BA.1/BA.2 wave for anti-S antibody levels above 800 IU/mL (HR 0.30, 95% CI 0.22-0.41). However, we did not detect a reduction in hazard among uninfected participants. These results provide reassuring insights into the continued interpretation of SARS-CoV-2 binding antibody measurements as an independent marker of protection at both the individual and population levels.
Mots-clé
Humans, COVID-19, SARS-CoV-2, Antibodies, Viral, Immune Evasion, Kinetics, Antibodies, Neutralizing
Pubmed
Web of science
Open Access
Oui
Création de la notice
31/05/2023 8:39
Dernière modification de la notice
08/08/2024 6:35
Données d'usage